Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.